DeepLook Medical

From clinical trial diversity to regulatory and investment hurdles, advancing women's health in MedTech isn’t easy. But those who break through ?????? ???????????????? ??????????. We're bringing together ???????? ???? ?????????? ?????????????? ?????? ?????????? ?????????????? ???? ?????? ?????????? for our next live panel discussion. As part of our ???? ???????? ??????????’?? ???????????? ???????????? campaign, this free event will bring together a powerhouse panel (really!) of influential women to share real-world strategies for accelerating progress in women’s health. ?? ?????? ??????????: Marissa Fayer – CEO, HERhealthEQ ?????? DeepLook Medical Megan Callanan – US & Global Regulatory Lead, Natural Cycles° Stephanie Kladakis – EVP, Chief Technology & Regulatory Officer, AgNovos Bioscience Alexia Haralambous – Senior Principal, RQM+ Moderated by Jaishankar Kutty, Ph.D., VP of Global Regulatory Affairs at RQM+ ???????? ????'???? ??????????: ???? The business case for investing in women’s health ?? The toughest regulatory & market hurdles—and how to overcome them ???? How clinical trials are evolving to close the data gap ?? Lessons from industry pioneers bringing innovations to life ?????????? ??????????????: ?? March 20 | 11am ET / 4pm CET | Live panel with Q&A throughout ?? Have tough questions? ?????? ????????. This is a live, unfiltered conversation designed to give you practical, actionable insights. ???????? ???? ???? ?????? ?????????? at the link in the comments! ?? #MedTech #WomensHealth #ClinicalTrials #RegulatoryAffairs

"Breast?cancer is the most common cancer in women in the United States, except for skin cancers. It accounts for about 30% (or 1 in 3) of all new female cancers each year. The?American Cancer Society's estimates for breast cancer in the United States for 2025 are: ?? About 316,950 new cases of invasive breast cancer will be diagnosed in women. ??About 59,080 new cases of?ductal carcinoma in situ (DCIS)?will be diagnosed. ??About 42,170 women will die from breast cancer." All of these women deserve better tools to help them get the answers they deserve in a timely manner to help them make the most informed decisions."

"What it means to have dense breasts as Julia Bradbury backs AI cancer detection" Learn more about Julia's cancer journey and why she believes women with dense breasts deserve better tools: https://lnkd.in/dY4BEVBv

First day at European Society of Radiology complete ?? ! Come meet our CEO Marissa Fayer at Barco's booth (#207) to learn more about how we are using AI to detect cancer in dense breasts!

Will you be at European Society of Radiology 2025? Come by the Barco booth to learn more about DL Precise?, our FDA-cleared imaging software. We provide one-click segmentation and vivid tumor morphology display across multiple modalities, bringing clarity and confidence to every stage of care. We believe in a future where data-driven imaging enhances personalized, efficient treatment for every patient. Connect with our CEO Marissa Fayer if you'd like to set up a time to meet. See you there!

"More than 40-percent of women have dense breast tissue, putting them at an increased risk of cancer. Dense tissue can mask tumors on a mammogram because dense tissue and tumors are both white. It has delayed critical diagnoses in women across America, as our years of?reporting?have revealed." This is why we exist. Women with dense breast *deserve* and *NEED* better tools to help ensure providers can detect and diagnose lesions with unprecedented accuracy. Our DL Precise? Technology?is the only FDA-cleared solution for dense tissue imaging. It integrates seamlessly into your workflow, providing real-time lesion-level visualization to improve efficiency and reduce unnecessary diagnostics.

We are proud to partner with Barco to?empower providers to detect and diagnose lesions with unprecedented accuracy. ??

We are thrilled to announce our collaboration with?Sharla Fisher of Fisher Strategic Advisors.?Sharla?will join our DeepLook Medical team as the fractional VP of Commercial Operations. With her extensive healthcare expertise and a proven track record in forming strategic partnerships,?Sharla?will drive the strategy for DL Precise, our on demand measurement and?segmentation radiology solution. We are excited to have?Sharla's experienced leadership guiding impactful solutions for our organization!

Happy International Day of Women and Girls in Science! ?? "While women joined the American Association for Cancer Research in increasing numbers through the first half of the 20th?century, it wasn’t until 1957 that a woman joined the AACR Board of Directors—Elizabeth C. Miller, PhD. In 1961, the members of the AACR elected Thelma B. Dunn, MD, President, marking the first time a woman would hold this distinguished post. Although the change was not immediate, Dunn’s presidency laid a foundation for female leadership of the AACR. In all, 14 women have served as President of the AACR, including Charlotte Friend, PhD, 1975-1976; Elizabeth C. Miller, PhD, 1976-1977; Gertrude B. Elion, DSc, 1983-1984; Margaret L. Kripke, PhD, 1993-1994; Louise C. Strong, MD, 1996-1997; Susan Band Horwitz, PhD, 2002-2003; Karen H. Antman, MD, 2003-2004; Lynn M. Matrisian, PhD, 2004-2005; Elizabeth H. Blackburn, PhD, 2010-2011; Judy E. Garber, MD, MPH, 2011-2012; Nancy E. Davidson, MD, 2016-2017; Elizabeth M. Jaffee, MD, 2018-2019; and Elaine R. Mardis, PhD, 2019-2020. Many of these women have also been elected Fellows of the AACR Academy, serving as part of the AACR’s global brain trust and providing expertise in all areas of cancer science." We love this list that AACR compiled to share the history of women who have led the way for this important organization! https://lnkd.in/eqhCnxhk

This is exactly why women with dense breasts deserve better! With DL Precise?, our FDA-cleared imaging software, we provide one-click segmentation and vivid tumor morphology display across multiple modalities, bringing clarity and confidence to every stage of care. We believe in a future where data-driven imaging enhances personalized, efficient treatment for every patient, and we are proud to partner with innovators in medical imaging worldwide. Great post by Siobhan Freeney: